What's all the FLAP about?: 5-lipoxygenase-activating protein inhibitors for inflammatory diseases

Trends in Pharmacological Sciences

Volumn 29, Issue 2, 2008, Pages 72-78

  Evans, Jilly F ^a   Ferguson, Andrew D ^b   Mosley, Ralph T ^b   Hutchinson, John H ^a  

^a Amira Pharmaceuticals   (United States)

^b MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 CYCLOPENTYL 2 [4 (2 QUINOLINYLMETHOXY)PHENYL]ACETIC ACID; 3 [3 TERT BUTYLTHIO 1 (4 CHLOROBENZYL) 5 (2 QUINOLINYLMETHOXY) 2 INDOLYL] 2,2 DIMETHYLPROPIONIC ACID; 3 [3 TERT BUTYLTHIO 1 (4 CHLOROBENZYL) 5 ISOPROPYL 2 INDOLYL] 2,2 DIMETHYLPROPIONIC ACID; ARACHIDONATE 5 LIPOXYGENASE ACTIVATING PROTEIN; ARACHIDONATE 5 LIPOXYGENASE ACTIVATING PROTEIN INHIBITOR; ARACHIDONIC ACID; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; LEUKOTRIENE DERIVATIVE; LEUKOTRIENE RECEPTOR; LEUKOTRIENE RECEPTOR BLOCKING AGENT; MONTELUKAST; PRANLUKAST; PROSTAGLANDIN; PROTEIN INHIBITOR; UNCLASSIFIED DRUG; ZAFIRLUKAST; ZILEUTON;

ALLERGIC RHINITIS; ARTICLE; ASTHMA; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; DRUG BINDING; DRUG INHIBITION; DRUG STRUCTURE; FATTY ACID METABOLISM; HEART INFARCTION; HUMAN; INFLAMMATION; INNATE IMMUNITY; LIVER TOXICITY; NONHUMAN; PRIORITY JOURNAL; PROTEIN ANALYSIS; RESPIRATORY TRACT DISEASE; RESTENOSIS; STROKE;

ANIMALS; ASTHMA; CARDIOVASCULAR DISEASES; CARRIER PROTEINS; CONTROLLED CLINICAL TRIALS AS TOPIC; DRUG DELIVERY SYSTEMS; DRUG DESIGN; DRUG EVALUATION, PRECLINICAL; HUMANS; LEUKOTRIENES; MEMBRANE PROTEINS;

EID: 38749113897     PISSN: 01656147     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.tips.2007.11.006     Document Type: Article

References (59)

1. Murphy R.C., and Gijon M.A. Biosynthesis and metabolism of leukotrienes. Biochem. J. 405 (2007) 379-395
2. Mandal A.K., et al. The membrane organization of leukotriene synthesis. Proc. Natl. Acad. Sci. U. S. A. 101 (2004) 6587-6592
3. Young R.N. Inhibitors of 5-lipoxygenase: a therapeutic potential yet to be fully realized?. Eur. J. Med. Chem. 34 (1999) 671-685
4. Peters-Golden M., and Henderson W.R. Mechanisms of disease. Leukotrienes. N. Engl. J. Med. 357 (2007) 1841-1854
5. Ciana P., et al. The orphan receptor GPR17 identified as a new dual uracil/cysteinyl-leukotrienes receptor. EMBO J. 25 (2006) 4615-4627
6. Bresell A., et al. Bioinformatic and enzymatic characterization of the MAPEG superfamily. FEBS J. 272 (2005) 1688-1703
7. Peters-Golden M., et al. Leukotrienes: underappreciated mediators of innate immune responses. J. Immunol. 174 (2005) 589-594
8. Funk C.D. Leukotriene modifiers as potential therapeutics for cardiovascular disease. Nat. Rev. Drug Discov. 4 (2005) 664-672
9. Gillard J., et al. L-663,536 (MK-886) (3-[1-(4-chlorobenzyl)-3-t-butyl-thio-5-isopropylindol-2-yl]-2,2-dimethylpropanoic acid), a novel, orally active leukotriene biosynthesis inhibitor. Can. J. Physiol. Pharmacol. 67 (1989) 456-464
10. Muller-Peddinghaus R., et al. BAY X1005, a new inhibitor of leukotriene synthesis: In vivo inflammation pharmacology and pharmacokinetics. J. Pharmacol. Exp. Ther. 267 (1993) 51-57
11. Evans J.F., et al. 5-Lipoxygenase-activating protein is the target of a quinoline class of leukotriene synthesis inhibitors. Mol. Pharmacol. 40 (1991) 22-27
12. Miller D.K., et al. Identification and isolation of a membrane protein necessary for leukotriene production. Nature 343 (1990) 278-281
13. Dixon R.A.F., et al. Requirement of a 5-lipoxygenase-activating protein for leukotriene synthesis. Nature 343 (1990) 282-284
14. 4. Proc. Natl. Acad. Sci. U. S. A. 91 (1994) 7663-7667
15. Brideau C., et al. Pharmacology of MK-0591 (3-[1-(4-chlorobenzyl)-3-(t-butylthio)-5-(quinolin-2-ylmethoxy)-indol-2-yl]-2,2-dimethylpropanoic acid), a potent, orally active leukotriene biosynthesis inhibitor. Can. J. Physiol. Pharmacol. 70 (1992) 799-807
16. Charleson S., et al. Characterization of a 5-lipoxygenase-activating protein binding assay: Correlation of affinity for 5-lipoxygenase-activating protein with leukotriene synthesis inhibition. Mol. Pharmacol. 41 (1992) 873-879
17. Vickers P.J., et al. Identification of amino acid residues of 5-lipoxygenase-activating protein essential for the binding of leukotriene biosynthesis inhibitors. Mol. Pharmacol. 42 (1992) 94-102
18. Kolasa T., et al. Symmetrical Bis(heteroarylmethoxyphenyl)alkylcarboxylic acids as inhibitors of leukotriene biosynthesis. J. Med. Chem. 43 (2000) 3322-3334
19. 4 synthase. J. Med. Chem. 38 (1995) 4538-4547
20. Berger W., et al. Zileuton: clinical implications of 5-lipoxygenase inhibition in severe airway disease. Int. J. Clin. Pract. 61 (2007) 663-676
21. Friedman B.S., et al. Oral leukotriene inhibitor (MK-886) blocks allergen-induced airway responses. Am. Rev. Respir. Dis. 147 (1993) 839-844
22. Dahlen B., et al. Inhibition of allergen-induced airway obstruction and leukotriene generation in atopic asthmatic subjects by the leukotriene biosynthesis inhibitor BAY X1005. Thorax 52 (1997) 342-347
23. Diamant Z., et al. The effect of MK-0591, a novel 5-lipoxygenase-activating protein inhibitor, on leukotriene biosynthesis and allergen-induced airway responses in asthmatic subjects in vivo. J. Allergy Clin. Immunol. 95 (1995) 42-51
24. Hui K.P., et al. Effect of a 5-lipoxygenase inhibitor on leukotriene generation and airway responses after allergen challenge in asthmatic patients. Thorax 46 (1991) 184-189
25. Chapman K.R., et al. The efficacy of an oral inhibitor of leukotriene synthesis (MK-0591) in asthmatics treated with inhaled steroids. Am. J. Respir. Crit. Care Med. 149 (1994) A215
26. Storms W., et al. Treating asthma by blocking the lipoxygenase pathway. Am. J. Respir. Crit. Care Med. 151 (1995) A377
27. Kuzuya T., et al. Polymorphonuclear leukocyte activity and ventricular arrhythmia in acute myocardial infarction. Am. J. Cardiol. 62 (1988) 868-872
28. 4 production in human atherosclerotic plaques. Biomed. Biochim. Acta 47 (1988) S182-S185
29. Spanbroek R., et al. Expanding the expression of the 5-lipoxygenase pathway within the arterial wall during human atherogenesis. Proc. Natl. Acad. Sci. U. S. A. 100 (2003) 1238-1243
30. 4 hydrolase in human atherosclerotic lesions correlates with symptoms of plaque instability. Proc. Natl. Acad. Sci. U. S. A. 103 (2006) 8161-8166
31. Rossoni G., et al. Myocardial protection by the leukotriene synthesis inhibitor BAY X1005: importance of transcellular biosynthesis of cysteinyl-leukotrienes. J. Pharmacol. Exp. Ther. 276 (1996) 335-341
32. Jawien J., et al. Inhibition of five lipoxygenase-activating protein (FLAP) by MK-886 decreases atherosclerosis in apoE/LDLR-double knockout mice. Eur. J. Clin. Invest. 36 (2006) 141-146
33. Back M., et al. 5-Lipoxygenase-activating protein. A potential link between innate and adaptive immunity in atherosclerosis and adipose tissue inflammation. Circ. Res. 100 (2007) 946-949
34. Mehrabian M., et al. Identification of 5-lipoxygenase as a major gene contributing to atherosclerosis susceptibility in mice. Circ. Res. 91 (2002) 120-126
35. Zhao L., et al. The 5-lipoxygenase pathway promotes pathogenesis of hyperlipidemia-dependent aortic aneurysm. Nat. Med. 10 (2004) 966-973
36. Ahluwalia N., et al. Inhibited aortic aneurysm formation in BLT1-deficient mice. J. Immunol. 179 (2007) 691-697
37. Cao R.Y., et al. Angiotensin-II-induced abdominal aortic aneurysm occurs independently of the 5-lipoxygenase pathway in apolipoprotein E-deficient mice. Prostag. Oth. Lipid M. 84 (2007) 34-42
38. Helgadottir A., et al. The gene encoding 5-lipoxygenase-activating protein confers risk of myocardial infarction and stroke. Nat. Genet. 36 (2004) 233-239
39. 4 hydrolase confers ethnic specific risk of myocardial infarction. Nat. Genet. 38 (2006) 68-74
40. Iovannisci D.M., et al. Association between a leukotriene C4 synthase gene promoter polymorphism and coronary artery calcium in young woman. The Muscatine study. Aterioscler. Thromb. Vasc. Biol. 27 (2007) 394-399
41. Kaushal R., et al. Association of ALOX5AP with ischemic stroke: a population-based case-control study. Hum. Genet. 121 (2007) 601-607
42. Jeng J.R. Plasma C-reactive protein and 5-lipoxygenase-activating protein gene promoter poly-a polymorphism in patients with coronary artery disease. Cardiology 109 (2008) 25-32
43. Larson M.G., et al. Framingham Heart Study 100K project: genome-wide associations for cardiovascular disease outcomes. BMC Med. Genet. 8 (2007) S5
44. Zee R.Y., et al. Genetic variants of arachidonate 5-lipoxygenase-activating protein, and risk of incident myocardial infarction and ischemic stroke: a nested case-control approach. Stroke 37 (2006) 2007-2011
45. Koch W., et al. No association of polymorphisms in the gene encoding 5-lipoxygenase-activating protein and myocardial infarction in a large central European population. Genet. Med. 9 (2007) 123-129
46. O'Donnell C.J., et al. Genome-wide association study for subclinical atherosclerosis in major arterial territories in the NHLBI's Framingham Heart Study. BMC Med. Genet. 8 (2007) S4
47. 4) hydrolase genes. J. Am. Med. Assoc. 293 (2005) 2245-2256
48. Ferguson A.D., et al. Crystal structure of inhibitor bound 5-lipoxygenase-activating protein. Science 317 (2007) 510-512
49. Ago H., et al. Crystal structure of a human membrane protein involved in cysteinyl leukotriene biosynthesis. Nature 448 (2007) 609-612
50. 4 synthase. Nature 448 (2007) 613-616
51. Crippen G.M., and Havel T.F. Distance Geometry and Molecular Conformation (1988), Research Studies Press, Wiley
52. Halgren T.A. MMFF VI. MMFF94s option for energy minimization studies. J. Comput. Chem. 20 (1999) 720-729
53. Miller M.D., et al. SQ: a program for rapidly producing pharmacologically relevant molecular superpositions. J. Med. Chem. 42 (1999) 1505-1514
54. Hutchinson J.H., et al. Development of L-689,065 - the prototype of a new class of potent 5-lipoxygenase inhibitors. Bioorg. Med. Chem. Lett. 2 (1992) 1699-1702
55. Woods K.W., et al. o-Alkylcarboxylate oxime and N-hydroxyurea analogs of substituted indole leukotriene biosynthesis inhibitors. Bioorg. Med. Chem. Lett. 6 (1996) 1547-1552
56. Chu, L et al., Merck & Co Inc. Diphenyl substituted alkanes. Patent application. WO2006/044602
57. Hutchinson, J.H. et al. Amira Pharmaceuticals. 5-Lipoxygenase-activating protein (FLAP) inhibitors. Patent application US2007/0105866
58. Byrum R.S., et al. Role of the 5-lipoxygenase-activating protein (FLAP) in murine acute inflammatory responses. J. Exp. Med. 185 (1997) 1065-1075
59. Chen X.S., et al. Role of leukotrienes revealed by targeted disruption of the 5-lipoxygenase gene. Nature 372 (1994) 179-182